BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Song M, Ang TL. Second and third line treatment options for Helicobacter pylori eradication. World J Gastroenterol 2014; 20(6): 1517-1528 [PMID: 24587627 DOI: 10.3748/wjg.v20.i6.1517]
URL: https://www.wjgnet.com/1007-9327/full/v20/i6/1517.htm
Number Citing Articles
1
Ravishankar Ram M., Xinsheng Teh, Tamayanthi Rajakumar, Khean Lee Goh, Alex Hwong Ruey Leow, Bee Hoon Poh, Vanitha Mariappan, Esaki M Shankar, Mun Fai Loke, Jamuna Vadivelu. Polymorphisms in the host CYP2C19 gene and antibiotic-resistance attributes ofHelicobacter pyloriisolates influence the outcome of triple therapyJournal of Antimicrobial Chemotherapy 2019; 74(1): 11 doi: 10.1093/jac/dky401
2
Adeola O Adebisi, Barbara R Conway. Modification of drug delivery to improve antibiotic targeting to the stomachTherapeutic Delivery 2015; 6(6): 741 doi: 10.4155/tde.15.35
3
Seung Woo Lee, Sung Jin Moon, Sae Hee Kim, Sung Hee Jung, Kyung Ho Song, Sun Moon Kim, Jae Kyu Sung, Dong Soo Lee. The prolongation effect of ilaprazole-based standard triple therapy for Helicobacter pyloriMedicine 2020; 99(38): e22137 doi: 10.1097/MD.0000000000022137
4
Leila Manzouri, Farzaneh Zarei, Narjes Niazi, Moslem Sedaghattalab. Comparison of the Success Rate of Quadruple and Triple Antibiotic Therapy in Eradicating Helicobacter pylori Infection in Southwest of Iran: A Randomized Clinical TrialInternational Journal of Infection 2017; 4(3) doi: 10.5812/iji.15610
5
Guang-Hong Jheng, I-Chen Wu, Hsiang-Yao Shih, Meng-Chieh Wu, Fu-Chen Kuo, Huang-Ming Hu, Chung-Jung Liu, Wen-Hung Hsu, Chi-Tan Hu, Ming-Jong Bair, Chao-Hung Kuo, Deng-Chyang Wu, Ping-I Hsu. Comparison of Second-Line Quadruple Therapies with or without Bismuth forHelicobacter pyloriInfectionBioMed Research International 2015; 2015: 1 doi: 10.1155/2015/163960
6
Tiing Leong Ang, Kwong Ming Fock, Daphne Ang, Andrew Boon Eu Kwek, Eng Kiong Teo, Subbiah Dhamodaran. The Changing Profile ofHelicobacter pyloriAntibiotic Resistance in Singapore: A 15-Year StudyHelicobacter 2016; 21(4): 261 doi: 10.1111/hel.12291
7
Amin Talebi Bezmin Abadi. Helicobacter pylori treatment: New perspectives using current experienceJournal of Global Antimicrobial Resistance 2017; 8: 123 doi: 10.1016/j.jgar.2016.11.008
8
Ying An, Ya Wang, Shuang Wu, You-Hua Wang, Xing Qian, Zhen Li, Ying-Jun Fu, Yong Xie. Fourth-generation quinolones in the treatment of <i>Helicobacter pylori</i> infection: A meta-analysisWorld Journal of Gastroenterology 2018; 24(29): 3302-3312 doi: 10.3748/wjg.v24.i29.3302
9
Priscila Baptistella Yazbek, Ariane Biolcati Trindade, Chung Man Chin, Jean Leandro dos Santos. Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pyloriDigestive Diseases and Sciences 2015; 60(10): 2901 doi: 10.1007/s10620-015-3712-y
10
Kenichiro Okimoto, Makoto Arai, Keiko Saito, Shoko Minemura, Daisuke Maruoka, Tomoaki Matsumura, Tomoo Nakagawa, Tatsuro Katsuno, Chisato Ishii, Shota Murata, Masaharu Watanabe, Fumio Nomura, Osamu Yokosuka. Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line TherapiesInternational Scholarly Research Notices 2014; 2014: 1 doi: 10.1155/2014/631501
11
Hyun Chul Lim, Yong Jae Lee, Byoungrak An, Seung Woo Lee, Yong Chan Lee, Byung Soo Moon. Rifabutin‐based High‐dose Proton‐pump Inhibitor and Amoxicillin Triple Regimen as the Rescue treatment for Helicobacter pylori Helicobacter 2014; 19(6): 455 doi: 10.1111/hel.12147
12
Enrique Rodríguez de Santiago, Carlos Martín de Argila de Prados, Hector Miguel Marcos Prieto, Miguel Ãngel Jorge Turrión, Eva Barreiro Alonso, Alvaro Flores de Miguel, Cristobal de la Coba Ortiz, Carlos Rodríguez Escaja, Gustavo Pérez Álvarez, Carlos Ferre Aracil, Lara Aguilera Castro, Ana García García de Paredes, Antonio Rodríguez Pérez, Agustin Albillos Martínez. Limited effectiveness with a 10-day bismuth-containing quadruple therapy (Pylera® ) in third-line recue treatment for Helicobacter pylori infection. A real-life multicenter studyHelicobacter 2017; 22(5): e12423 doi: 10.1111/hel.12423
13
Ilaria M. Saracino, Matteo Pavoni, Angelo Zullo, Giulia Fiorini, Laura Saccomanno, Tiziana Lazzarotto, Guido Antonelli, Rossana Cavallo, Claudio Borghi, Dino Vaira. Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori InfectionEuropean Journal of Internal Medicine 2020; 81: 50 doi: 10.1016/j.ejim.2020.06.029
14
I. Thung, H. Aramin, V. Vavinskaya, S. Gupta, J. Y. Park, S. E. Crowe, M. A. Valasek. Review article: the global emergence ofHelicobacter pyloriantibiotic resistanceAlimentary Pharmacology & Therapeutics 2016; 43(4): 514 doi: 10.1111/apt.13497
15
Anil John, Saad Al Kaabi, Sanjay Doiphode, Prem Chandra, Manik Sharma, Ragesh Babu, Rafie Yacoub, Moutaz Derbala. Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?Indian Journal of Gastroenterology 2015; 34(5): 404 doi: 10.1007/s12664-015-0604-1
16
Per Boye Hansen, Milena Penkowa. RETRACTED ARTICLE: Bismuth adjuvant ameliorates adverse effects of high-dose chemotherapy in patients with multiple myeloma and malignant lymphoma undergoing autologous stem cell transplantation: a randomised, double-blind, prospective pilot studySupportive Care in Cancer 2017; 25(4): 1279 doi: 10.1007/s00520-016-3522-6
17
Yeon-Ji Kim, Woo Chul Chung. Eradication Therapy for Helicobacter pylori with Diagnostic Test for Clarithromycin ResistanceThe Korean Journal of Helicobacter and Upper Gastrointestinal Research 2019; 19(4): 225 doi: 10.7704/kjhugr.2019.0019
18
Peter Malfertheiner, Michael Selgrad. Helicobacter pyloriCurrent Opinion in Gastroenterology 2014; 30(6): 589 doi: 10.1097/MOG.0000000000000128
19
Thomas Regnath, Olaf Raecke, Axel Enninger, Ralf Ignatius. Increasing metronidazole and rifampicin resistance ofHelicobacter pyloriisolates obtained from children and adolescents between 2002 and 2015 in southwest GermanyHelicobacter 2017; 22(1): e12327 doi: 10.1111/hel.12327
20
Pedro Cortés, Alfred D. Nelson, Yan Bi, Fernando F. Stancampiano, Loren P. Murray, George G.A. Pujalte, Victoria Gomez, Dana M. Harris. Treatment Approach of Refractory Helicobacter pylori Infection: A Comprehensive ReviewJournal of Primary Care & Community Health 2021; 12: 215013272110140 doi: 10.1177/21501327211014087
21
Yoshihiro Hirata, Takako Serizawa, Satoki Shichijo, Nobumi Suzuki, Kosuke Sakitani, Yoku Hayakawa, Atsuo Yamada, Kazuhiko Koike. Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimenInternational Journal of Infectious Diseases 2016; 51: 66 doi: 10.1016/j.ijid.2016.08.019
22
I-Ting Wu, Seng-Kee Chuah, Chen-Hsiang Lee, Chih-Ming Liang, Lung-Sheng Lu, Yuan-Hung Kuo, Yi-Hao Yen, Ming-Luen Hu, Yeh-Pin Chou, Shih-Cheng Yang, Chung-Mou Kuo, Chung-Huang Kuo, Chun-Chih Chien, Yu-Shao Chiang, Shue-Shian Chiou, Tsung-Hui Hu, Wei-Chen Tai. Five-year sequential changes in secondary antibiotic resistance of <italic>Helicobacter pylori</italic> in TaiwanWorld Journal of Gastroenterology 2015; 21(37): 10669-10674 doi: 10.3748/wjg.v21.i37.10669
23
Javier P. Gisbert. Rifabutin for the Treatment of Helicobacter pylori Infection: A ReviewPathogens 2020; 10(1): 15 doi: 10.3390/pathogens10010015